Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 1 · 16.7%Moderate 2 · 33.3%High 0 · 0%

All causes of death · people requiring prevention of venous thromboembolism

Fondaparinux showed no clear difference in all causes of death compared with LMWH (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.88 [0.63, 1.22]
11 studies · 12400 participants
Moderate

All causes of death · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 236 participants
Very low

All causes of death · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 236 participants
Very low

All causes of death · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

All causes of death · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Low

All causes of death · people requiring prevention of venous thromboembolism

Fondaparinux showed no clear difference in all causes of death compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.76 [0.48, 1.22]
8 studies · 6674 participants
Moderate